Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsSina Nikayin, MD
Assistant Professor Adjunct in PsychiatryAbout
Copy Link
Titles
Assistant Professor Adjunct in Psychiatry
Biography
Sina Nikayin, MD, is a psychiatrist at the Yale Interventional Psychiatry Service (IPS). Interventional psychiatrists utilize advanced modalities and procedures to treat patients who are resistant to other treatments such as medications, and who may be at higher risk of medical and psychiatric complications because of the severity of their illness.
At the IPS, Dr. Nikayin works with a variety of therapies, including ketamine, esketamine (Spravato), electroconvulsive therapy (ECT), and transcranial magnetic stimulation (TMS) to treat treatment-resistant depression (TRD). Some of these modalities can also be used to treat other psychiatric disorders, such as bipolar disorders and schizoaffective disorder.
“Interventional modalities can provide significant relief and improvement to patients who have been suffering from depression or other psychiatric disorders for a long time, have tried and failed multiple treatments, and may have been suffering for many years,” says Dr. Nikayin.
It’s rewarding to be able to help these patients find relief, he adds. “For me, the highest reward is when my patients experience relief from their symptoms, when they tell me that they had almost forgotten what it was like to not feel the burden of depression. Once again, they are able to genuinely laugh or enjoy activities they used to love.”
In addition to his clinical work, Dr. Nikayin is an assistant professor of psychiatry at Yale School of Medicine, where he and his colleagues are involved in multiple clinical research projects designed to address such topics as the effectiveness of ketamine as an antidepressant in Parkinson’s disease, the use of cognitive behavioral therapy alongside esketamine in the treatment of depression with suicidal ideation, and the effectiveness and safety of ECT compared to ketamine in treatment of depression.
Appointments
Psychiatry
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Center for Brain & Mind Health
- Psychiatric Symptoms in Neurology Research Program
- Psychiatry
- Yale Depression Research Program
Education & Training
- Resident
- Yale School of Medicine
- MD
- Tehran University Of Medical Sciences
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0001-9024-038X
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Gerard Sanacora, PhD, MD
Samuel Wilkinson, MD
Anahita Rabiee, MD, MHS
Greg Rhee, PhD, FACE
Robert Ostroff, MD
Brian Pittman
Ketamine
Electroconvulsive Therapy
Delirium
Catatonia
Patient Reported Outcome Measures
Publications
Featured Publications
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Iqbal S, Malone D, Wolski K, Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Chang L, Collins K, Costi S, Jha M, Krishnan K, Nikayin S, Ostroff R, Reti I, Wilkinson S, Hu B, Barnett B, Nissen S. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. The New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchCitationsAltmetricEvaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting
Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, Wilkinson ST. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. JAMA Psychiatry 2022, 79: 736-738. PMID: 35544190, PMCID: PMC9096687, DOI: 10.1001/jamapsychiatry.2022.1074.Peer-Reviewed Original ResearchCitationsAltmetricAdvanced training in interventional psychiatry
Nikayin S, Taylor JJ, Ostroff RB. Advanced training in interventional psychiatry. Journal Of The Neurological Sciences 2021, 434: 120093. PMID: 34974201, DOI: 10.1016/j.jns.2021.120093.Peer-Reviewed Original ResearchCitationsAltmetricThe Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents
Colloca L, Nikayin S, Sanacora G. The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents. JAMA Psychiatry 2023, 80: 867-868. PMID: 37405764, PMCID: PMC10868530, DOI: 10.1001/jamapsychiatry.2023.1412.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords
2025
Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine
Santucci M, Katz R, Pittman B, Nikayin S, Wilkinson S. Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine. Psychopharmacology 2025, 1-9. PMID: 40973876, DOI: 10.1007/s00213-025-06896-7.Peer-Reviewed Original ResearchCitationsDoes BMI matter when treating depression with esketamine? A retrospective analysis of real-world data
Ansari M, Rhee T, Santucci M, Nikayin S. Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data. Journal Of Affective Disorders 2025, 381: 22-28. PMID: 40185405, DOI: 10.1016/j.jad.2025.03.198.Peer-Reviewed Original ResearchCitationsAltmetric
2024
The genetics of severe depression
Franklin C, Achtyes E, Altinay M, Bailey K, Bhati M, Carr B, Conroy S, Husain M, Khurshid K, Lencz T, McDonald W, Mickey B, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti I, Selek S, Sanacora G, Trapp N, Viswanath B, Wright J, Sullivan P, Zandi P, Potash J. The genetics of severe depression. Molecular Psychiatry 2024, 30: 1117-1126. PMID: 39406997, DOI: 10.1038/s41380-024-02731-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricEfficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchCitationsAltmetricBlood pressure changes during ketamine infusion for the treatment of depression
Ansari M, Pittman B, Tylee D, Ostroff R, Wilkinson S, Nikayin S. Blood pressure changes during ketamine infusion for the treatment of depression. General Hospital Psychiatry 2024, 90: 62-67. PMID: 38991311, DOI: 10.1016/j.genhosppsych.2024.07.001.Peer-Reviewed Original ResearchCitationsAltmetricKetamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.Peer-Reviewed Original ResearchCitationsAltmetric
News
Copy Link
News
- October 02, 2024
Bipolar Disorder Patients Respond to Ketamine, Esketamine Treatment
- May 02, 2024Source: The New England Journal of Medicine
Depression — Understanding, Identifying, and Diagnosing
- July 06, 2023Source: JAMA Psychiatry
The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents
Get In Touch
Copy Link